SGLT2 inhibitors (SGLT2i) have been shown to improve cardiorenal endpoints in patients with type 2 diabetes (T2DM), CKD, and chronic heart failure with reduced ejection fraction (HFrEF) [4–6]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.